




The relative strengths and weaknesses of Avadel Pharmaceuticals PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avadel Pharmaceuticals PLC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 89% points. The greatest weakness of Avadel Pharmaceuticals PLC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 115% points.

The company's Economic Capital Ratio, given in the ranking table, is 230%, being 33% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	166,306
Cost of Goods Sold	10,921
Intangible Assets	34,316
Liabilities, Current	48,788
Liabilities, Non-Current	2,894
Other Assets	11,739
Other Compr. Net Income	-15,234
Other Expenses	87,554
Other Liabilities	95,430
Other Net Income	13,245
Other Revenues	173,209
Property and Equipment	2,616
Research and Development	25,608
Selling, General and Administrative Expense	21,712

Output Variable	Value in 1000 USD
Assets	214,977
Liabilities	147,112
Expenses	145,795
Revenues	173,209
Stockholders Equity	67,865
Net Income	40,659
Comprehensive Net Income	33,042
BaseVar	354,786
ECR before LimitedLiability	100%
Economic Capital Ratio	230%